Management expects disposables and full system sales to grow in line with increased procedure acceptance, but notes that many procedures are currently performed under the pilot program or clinical ...
SALT LAKE CITY, March 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN) (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces the launch of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results